PL3442537T3 - (+)-azasetron do zastosowania w leczeniu zaburzeń ucha - Google Patents

(+)-azasetron do zastosowania w leczeniu zaburzeń ucha

Info

Publication number
PL3442537T3
PL3442537T3 PL17717441.4T PL17717441T PL3442537T3 PL 3442537 T3 PL3442537 T3 PL 3442537T3 PL 17717441 T PL17717441 T PL 17717441T PL 3442537 T3 PL3442537 T3 PL 3442537T3
Authority
PL
Poland
Prior art keywords
azasetron
treatment
ear disorders
ear
disorders
Prior art date
Application number
PL17717441.4T
Other languages
English (en)
Inventor
Jonas DYHRFJELD-JOHNSEN
Original Assignee
Sensorion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sensorion filed Critical Sensorion
Priority claimed from PCT/EP2017/059058 external-priority patent/WO2017178645A1/en
Publication of PL3442537T3 publication Critical patent/PL3442537T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL17717441.4T 2016-04-14 2017-04-14 (+)-azasetron do zastosowania w leczeniu zaburzeń ucha PL3442537T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662322690P 2016-04-14 2016-04-14
EP16180192 2016-07-19
PCT/EP2017/059058 WO2017178645A1 (en) 2016-04-14 2017-04-14 (+)-azasetron for use in the treatment of ear disorders

Publications (1)

Publication Number Publication Date
PL3442537T3 true PL3442537T3 (pl) 2024-07-15

Family

ID=65588799

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17717441.4T PL3442537T3 (pl) 2016-04-14 2017-04-14 (+)-azasetron do zastosowania w leczeniu zaburzeń ucha

Country Status (18)

Country Link
US (2) US11612605B2 (pl)
EP (1) EP4335508A3 (pl)
JP (1) JP7158723B2 (pl)
CN (1) CN109310698B (pl)
AU (1) AU2023202897B2 (pl)
CL (1) CL2018002930A1 (pl)
DK (1) DK3442537T3 (pl)
ES (1) ES2975016T3 (pl)
FI (1) FI3442537T3 (pl)
HR (1) HRP20240453T1 (pl)
HU (1) HUE066000T2 (pl)
IL (1) IL262305B (pl)
MX (1) MX384045B (pl)
NZ (1) NZ747201A (pl)
PL (1) PL3442537T3 (pl)
RS (1) RS65379B1 (pl)
SI (1) SI3442537T1 (pl)
ZA (1) ZA201806894B (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3909579A1 (en) * 2015-05-18 2021-11-17 Sensorion Calcineurin inhibitors of the setron family for the treatment of hearing loss

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695578A (en) 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
US5360800A (en) 1987-09-03 1994-11-01 Glaxo Group Limited Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives
CA1304082C (en) 1987-10-22 1992-06-23 Tetsuya Tahara Benzoxazine compounds and pharmaceutical use thereof
GB9423511D0 (en) 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
GB0009914D0 (en) 2000-04-20 2000-06-07 Metris Therapeutics Limited Device
GB0104554D0 (en) 2001-02-23 2001-04-11 Glaxo Group Ltd New uses
US20030044356A1 (en) 2001-04-20 2003-03-06 Jin Auh Composition for nasal solution sprays having effective component of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one)
WO2003071986A2 (en) * 2002-02-22 2003-09-04 Control Delivery Systems, Inc. Method for treating otic disorders
GB0213869D0 (en) 2002-06-17 2002-07-31 Arakis Ltd The treatment of pain
AU2004204827B2 (en) 2003-01-13 2006-06-29 Dynogen Pharmaceuticals, Inc. Method of treating nausea, vomiting, retching or any combination thereof
TWI355936B (en) 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
US20040204466A1 (en) 2003-04-14 2004-10-14 Orchid Chemicals And Pharmaceuticals Ltd. Treatment of bronchial asthma using 5-HT3 receptor antagonists
US20070265329A1 (en) 2006-05-12 2007-11-15 Devang Shah T Methods for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)
EP2244735A4 (en) 2007-10-02 2011-02-23 Avaxia Biologics Inc ANTIBODY THERAPY FOR USE IN THE DIGESTIVE TUBE
JP5491502B2 (ja) 2008-07-14 2014-05-14 オトノミ―,インク. 制御放出アポトーシス調節化合物および耳の障害の処置のための方法
ES2432618T3 (es) * 2009-05-20 2013-12-04 Inserm (Institut National De La Santé Et De La Recherche Medicale) Antagonistas del receptor 5-HT3 de serotonina para usar en el tratamiento o prevención de una patología del oído interno con déficit vestibular
KR101779991B1 (ko) * 2009-05-20 2017-09-19 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 병소성 전정 질환을 치료하기 위한 세로토닌 5-ht3 수용체 길항제의 용도
CN101786963B (zh) 2010-03-03 2013-05-08 山东众诚药业股份有限公司 阿扎司琼中间体的合成方法
EP2817009A1 (en) 2012-02-23 2014-12-31 INSERM - Institut National de la Santé et de la Recherche Médicale Calcineurin inhibitors for use in the treatment of lesional vestibular disorders
EP2872128B1 (en) 2012-07-16 2020-02-19 Cornell University Nicotinamide riboside to treat hearing loss
US9603935B2 (en) * 2013-07-31 2017-03-28 Bluepharma Oral dispersible films
CN104557906A (zh) 2015-01-21 2015-04-29 扬子江药业集团四川海蓉药业有限公司 一种盐酸阿扎司琼的制备方法
EP3909579A1 (en) 2015-05-18 2021-11-17 Sensorion Calcineurin inhibitors of the setron family for the treatment of hearing loss

Also Published As

Publication number Publication date
MX2018012587A (es) 2019-03-07
IL262305B (en) 2022-03-01
US20190083503A1 (en) 2019-03-21
MX384045B (es) 2025-03-14
HRP20240453T1 (hr) 2024-06-21
EP4335508A2 (en) 2024-03-13
IL262305A (en) 2018-11-29
NZ747201A (en) 2023-02-24
HUE066000T2 (hu) 2024-06-28
ZA201806894B (en) 2023-03-29
SI3442537T1 (sl) 2024-05-31
CN109310698B (zh) 2021-12-24
US20230226071A1 (en) 2023-07-20
CN109310698A (zh) 2019-02-05
AU2023202897B2 (en) 2025-01-30
RS65379B1 (sr) 2024-04-30
CL2018002930A1 (es) 2019-02-15
DK3442537T3 (da) 2024-03-25
EP4335508A3 (en) 2024-07-10
US11612605B2 (en) 2023-03-28
JP2019513780A (ja) 2019-05-30
AU2023202897A1 (en) 2023-05-25
ES2975016T3 (es) 2024-07-02
JP7158723B2 (ja) 2022-10-24
FI3442537T3 (fi) 2024-04-04

Similar Documents

Publication Publication Date Title
IL289650A (en) Azolopyrimidine for the treatment of cancer-related disorders
IL290150A (en) Compounds and methods for treating chronic pain
HUE061761T2 (hu) Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében
GB201405232D0 (en) Apparatus and methods for the treatment of ocular disorders
PL3297628T3 (pl) Azasetron do stosowania w leczeniu niedosłuchu
IL258032A (en) Compounds and preparations for the treatment of ocular disorders
PL3277280T3 (pl) Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych
HUE039750T2 (hu) Hidroxi-buspiron mozgászavarok kezelésére
IL270701A (en) Neurotrophins for use in the treatment of hearing loss
IL275349A (en) Use of hM4Di in the treatment of seizure disorders
IL246855A0 (en) Materials for use in the treatment of retinitis
GB201607388D0 (en) Treatment of impulsivity-related disorders
IL251736B (en) Methods and compositions for the treatment of radiation-related disorders
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism
PL3377089T3 (pl) Kompozycje zawierające cdnf do zastosowania do donosowego leczenia chorób ośrodkowego układu nerwowego
IL269121A (en) Usl-311 for use in the treatment of cancer
ZA201806894B (en) (+)-azasetron for use in the treatment of ear disorders
PT3442537T (pt) (+)-azasetrom para utilização no tratamento de doenças do ouvido
EP3226865A4 (en) Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders
GB201602011D0 (en) Treating skin disorders
LT3297628T (lt) Azasetronas, skirtas naudoti klausos praradimo gydymui
HK1248110A1 (en) Plx-8394 or plx-7904 for use in the treatment of braf-v600-related diseases
GB201602784D0 (en) New treatment of CFTR-related disorders
GB201513345D0 (en) Methods for the treatment of Inflammatory disorders
GB201507113D0 (en) Methods for the treatment of inflammatory disorders